Characteristics and outcomes of young adults with Philadelphia-negative myeloproliferative neoplasms

被引:16
|
作者
Barzilai, Merav [1 ,2 ]
Kirgner, Ilya [1 ,2 ]
Avivi, Irit [1 ,2 ]
Ellis, Martin [2 ,3 ]
Dally, Najib [4 ,5 ]
Rozovski, Uri [2 ,6 ]
Lavi, Noa [5 ,7 ]
机构
[1] Sourasky Med Ctr, Div Hematol, Weitzman 6, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Meir Med Ctr, Div Hematol, Kefar Sava, Israel
[4] Ziv Med Ctr, Div Hematol, Safed, Israel
[5] Technion, Rappaport Fac Med, Haifa, Israel
[6] Rabin Med Ctr, Div Hematol, Petah Tiqwa, Israel
[7] Rambam Med Ctr, Div Hematol, Haifa, Israel
关键词
essential thrombocytosis; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; young adults; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; RISK-STRATIFICATION; POLYCYTHEMIA-VERA; THROMBOSIS; SURVIVAL; DISEASE; TRANSFORMATION; ADOLESCENT; DIAGNOSIS;
D O I
10.1111/ejh.13232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Approximately 10% of Philadelphia (Ph)-negative myeloproliferative neoplasms (NPM) are diagnosed at young adulthood. We aim to define the features of this group. Methods A multicenter retrospective study, including patients 18-45 years of age, diagnosed with Ph-negative MPN between 1985 and 2017. Results One hundred nine patients were included, 37 with polycythemia vera (34%), 54 with essential thrombocytosis (50%), 15 with primary myelofibrosis (PMF) (14%), and 3 with MPN unclassifiable (3%). Median age was 33 years and 62 (57%) were females. During a median follow-up of 8 years, 39 patients (37%) had at least one thrombotic event. 30/39 of events were venous (77%), 23/30 of which were splanchnic (77%). In 14/39 (36%), thrombosis preceded MPN diagnosis. In a multivariable analysis, only splenomegaly predicted for thrombosis (HR 5.6, CI: 1.4-22). The 10-year risk for secondary myelofibrosis was similar for ET and PV (0.13 vs 0.19, P = 0.51). The 10-year risk for leukemic transformation or mortality was significantly higher for PMF (0.3, P = 0.04). Conclusions The risks of mortality and of progression to MF/leukemia in young adults are similar to older population. Thrombotic events are frequently a presenting sign with a high incidence of venous, in particular splanchnic, events.
引用
收藏
页码:504 / 508
页数:5
相关论文
共 50 条
  • [21] Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
    Alshemmari, Salem H.
    Rajan, Reshmi
    Ameen, Reem
    Almazyad, Mazyad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (07): : 483 - 488
  • [22] Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
    Mora, Barbara
    Passamonti, Francesco
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (05) : 127 - 139
  • [23] The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
    Yoon, Seug Yun
    Won, Jong-Ho
    BLOOD RESEARCH, 2021, 56 : 44 - 50
  • [24] IMPORTANCE OF COAGULATION ASSESSMENT IN PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS PATIENTS
    Kabat, M. Gasior
    Pollmar, M. I. Rivas
    Roman, M. T. Alvarez
    Manzano, E. Monzon
    Butta, P. Acuna
    Salgado, E. G. Arias
    Salces, M. Martin
    Giulinai, M. Facal
    Marugan, P. Gonzalez
    De Bustamante, J. Martin
    Serrano, L. Gomez
    Barcenilla, S. Garcia
    Castro, C. Ramos
    Coll, N. Butta
    Yuste, V. Jimenez
    HAEMOPHILIA, 2023, 29 : 166 - 166
  • [25] Evaluation of thrombin generation in classical Philadelphia-negative myeloproliferative neoplasms
    Olteanu, Ariela Ligia
    Mihaila, Romeo-Gabriel
    Mihalache, Manuela
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2016, 24 (03): : 279 - 289
  • [26] How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy
    Robinson, Susan E.
    Harrison, Claire N.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : 625 - 634
  • [27] Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
    Barbara Mora
    Francesco Passamonti
    Current Hematologic Malignancy Reports, 2022, 17 : 127 - 139
  • [28] Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
    Kaplan, Jason B.
    Stein, Brady L.
    McMahon, Brandon
    Giles, Francis J.
    Platanias, Leonidas C.
    EBIOMEDICINE, 2016, 3 : 17 - 25
  • [29] Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
    Cacemiro, Maira da Costa
    Cominal, Jucara Gastaldi
    Tognon, Raquel
    Nunes, Natalia de Souza
    Simoes, Belinda Pinto
    de Figueiredo-Pontes, Lorena Lobo
    Bazzo Catto, Luiz Fernando
    Traina, Fabiola
    Souto, Elizabeth Xisto
    Zambuzi, Fabiana Albani
    Frantz, Fabiani Gai
    de Castro, Fabiola Attie
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (02) : 120 - 131
  • [30] Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms
    Hasselbalch, Hans Carl
    Kiladjian, Jean-Jacques
    Silver, Richard T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18) : E564 - E565